期刊文献+

健脾益肾补髓汤在治疗多发性骨髓瘤方面的临床疗效

下载PDF
导出
摘要 目的探讨健脾益肾补髓汤在治疗多发性骨髓瘤方面的临床疗效.方法:研究对象选取多发性骨髓瘤患者40 例,按照随机数列法分为对照组与观察组,每组20 例.对照组采用硼替佐米治疗,观察组采用健脾益肾补髓汤治疗.观察两组患者临床疗效.结果:对照组20 例患者经过治疗,完全缓解率为20.00%,接近完全缓解率为60.00%,总反应率为85.00%,观察组20 例患者经过治疗,完全缓解率为50.00%,接近完全缓解率为80.00%,总反应率为100.00%.两组患者临床治疗效果存在显著差异性,具备统计学意义(P〈0.05).结论:健脾益肾补髓汤在治疗多发性骨髓瘤方面疗效确切,具有极高的临床价值,值得进行推广应用. ObjectiveTo explore the clinical curative effect ofJianpi Yishen Huoxuebusui Tang in the treatment ofmultiple myeloma. Methods:the study object to select 40patients with multiple myeloma, according torandom sequences were divided into control group and observation group, 20 cases in each group. The control group using bortezomibtreatment, the observation group with spleen kidney marrow supplementing Decoction in the treatment of. To observe the clinical efficacy of the two groups. Results:20 patients in thecontrol group after treatment, complete remission rate was 20%, near complete remission rate was 60%, the total response rate was 85%, the observation group of 20 cases of patientsafter treatment, complete remission rate was 50%, near complete remission rate was 80%, the total response rate was 100%. The two groups of patients with clinicaltherapeutic effectof significant differences, with statistical significance (P 〈 0.05). Conclusion:Jianpi YishenHuoxuebusui Tang in the treatment of multiple myeloma,curative effect, has a very highclinical value, it is worth to be popularized and applied.
机构地区 解放军 解放军
出处 《世界中医药》 CAS 2015年第A01期35-35,共1页 World Chinese Medicine
关键词 硼替佐米 健脾益肾补髓汤 多发性骨髓瘤 临床疗效 Bortezomib Jianpi Yishen Huoxuebusui Tang multiple myeloma clinical effect
  • 相关文献

参考文献5

二级参考文献35

  • 1臧洪敏,陈君长,刘亦恒,刘润侠,王坤正.补肾活血方对大鼠成骨细胞增殖、分化及矿化的影响[J].中国中西医结合杂志,2005,25(12):1112-1114. 被引量:16
  • 2陈鹏,丘和明,宋爽,杨洪涌,刘安平,沈云,冷晓明,蓝海.补肾活血法辅助化疗治疗多发性骨髓瘤骨病16例疗效观察[J].新中医,2006,38(8):24-25. 被引量:13
  • 3柏长青,遆新宇,刘关键,李宁秀,董碧蓉.党参、黄芪提取物注射液对减轻肺癌患者化疗毒副反应和生存质量影响的研究[J].中国康复医学杂志,2006,21(8):707-709. 被引量:21
  • 4Attar M, Harousseau JL, Stoppa A, ct al. A prospective randomzed trial of autologous bone marrow transplantation and chemtherapy in multiple myeloma. N Engl J Med, 1996,335 (2) :91 - 97.
  • 5Attar M, Harousseau JL, Stoppa A, et al. A prospective high dose therapy in multiple myeloma an updated analysis of the IFM9Oprotocol. Blood, 1998,92 ( Supp 11 ) :418 - 422.
  • 6Lenhoff S, Hjorth M, Turrsson I, et al. Intensive therapy for multi- ple myeloma in patients younger than 60 years. Long - term re- sults focusing on the effect of the degree of response on survival and replapse patern after transplantation. Haematologiea,20(O ,91 (9) :1228 - 1233.
  • 7Child JA, Morgan G J, Davies FE, et al. High - dose chemotherapy with hematopoietic stem - cell rescue for multiple myeloma. N Engl J Med,2003,348(19) :1875 -1888.
  • 8Palumbo A, Anderson K. Multiple myeloma. N Engl J Med, 2011,364(11): 1046-1060.
  • 9Rajkumar SV. Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. Am J HematoU 2012,87(1): 78-88.
  • 10Rajkumar SV, Gahrton G, Bergsagel PL. Approach to the treatmentof multiple myeloma: A clash of philosophies. Blood, 2011,118 (12):3205-3211.

共引文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部